MYUNGMOON Pharm co.,Ltd
KRX:017180.KS
1999 (KRW) • At close September 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 169,567.373 | 152,134.941 | 137,759.902 | 127,852.856 | 149,346.277 | 147,498.532 | 140,137.943 | 142,179.739 | 125,100.92 | 105,420.702 | 103,723.479 | 100,538.969 | 125,619.902 | 105,183.289 | 97,191.219 | 77,390.43 | 60,927.94 |
| Cost of Revenue
| 75,051.801 | 74,034.142 | 75,422.116 | 78,861.731 | 80,912.967 | 73,048.384 | 60,933.137 | 66,001.437 | 62,422.141 | 51,254.833 | 52,634.734 | 53,966.771 | 56,756.617 | 48,062.634 | 43,844.387 | 31,753.248 | 26,271.52 |
| Gross Profit
| 94,515.572 | 78,100.799 | 62,337.786 | 48,991.125 | 68,433.31 | 74,450.148 | 79,204.806 | 76,178.302 | 62,678.779 | 54,165.869 | 51,088.745 | 46,572.198 | 68,863.285 | 57,120.655 | 53,346.832 | 45,637.182 | 34,656.42 |
| Gross Profit Ratio
| 0.557 | 0.513 | 0.453 | 0.383 | 0.458 | 0.505 | 0.565 | 0.536 | 0.501 | 0.514 | 0.493 | 0.463 | 0.548 | 0.543 | 0.549 | 0.59 | 0.569 |
| Reseach & Development Expenses
| 2,969.848 | 1,711.285 | 2,064.654 | 535.057 | 676.467 | 140.578 | 0 | 0 | 23.878 | 7.5 | 100.808 | 1,075.374 | 1,185.387 | 1,789.423 | 1,741.373 | 1,401.709 | 552.828 |
| General & Administrative Expenses
| 4,176.75 | 4,665.631 | 3,882.746 | 13,958.447 | 14,704.032 | 13,545.414 | 13,737.697 | 12,285.601 | 12,647.82 | 8,916.961 | 9,775.449 | 11,258.759 | 11,665.193 | 8,791.447 | 8,703.47 | 6,002.467 | 4,258.97 |
| Selling & Marketing Expenses
| 68,301.167 | 42,666.366 | 41,650.869 | 17,531.61 | 11,218.287 | 12,145.21 | 13,375.702 | 12,388.408 | 10,337.921 | 8,472.648 | 7,244.451 | 7,636.579 | 11,098.372 | 9,081.869 | 9,728.954 | 8,153.472 | 4,548.651 |
| SG&A
| 89,224.015 | 47,331.997 | 45,533.615 | 31,490.057 | 25,922.319 | 25,690.624 | 27,113.399 | 24,674.009 | 22,985.741 | 17,389.609 | 17,019.9 | 18,895.338 | 22,763.565 | 17,873.316 | 18,432.424 | 14,155.939 | 8,807.621 |
| Other Expenses
| -1,357.943 | 22,623.628 | 20,620.321 | 45,930.05 | 56,128.876 | 1,643.373 | 5,022.496 | 677.474 | -6,133.319 | 257.803 | 1,279.318 | 44.838 | 37.46 | -327.374 | -790.642 | -1,345.737 | -594.073 |
| Operating Expenses
| 93,551.806 | 71,666.91 | 68,218.59 | 77,955.164 | 82,727.662 | 69,513.238 | 71,731.548 | 66,120.555 | 65,149.034 | 50,439.806 | 46,983.321 | 50,296.976 | 57,915.145 | 47,983.172 | 46,580.52 | 37,759.194 | 24,884.314 |
| Operating Income
| 963.765 | 6,433.888 | -5,880.804 | -28,964.039 | -14,294.352 | 4,936.91 | 7,473.258 | 10,057.747 | -2,470.255 | 3,726.063 | 4,105.424 | -3,724.778 | 10,761.979 | 9,137.483 | 6,766.311 | 7,877.987 | 9,772.108 |
| Operating Income Ratio
| 0.006 | 0.042 | -0.043 | -0.227 | -0.096 | 0.033 | 0.053 | 0.071 | -0.02 | 0.035 | 0.04 | -0.037 | 0.086 | 0.087 | 0.07 | 0.102 | 0.16 |
| Total Other Income Expenses Net
| -5,745.399 | -3,781.682 | -717.315 | 1,669.528 | -4,889.639 | -3,044.293 | 2,633.214 | -1,870.268 | -7,982.487 | -3,039.707 | -3,008.403 | -5,768.642 | -5,113.532 | -3,640.78 | -3,595.143 | -2,031.218 | -1,155.479 |
| Income Before Tax
| -4,781.634 | 2,652.206 | -6,598.119 | -27,294.511 | -19,183.991 | 1,892.617 | 10,106.472 | 8,187.479 | -10,452.742 | 686.356 | 1,097.021 | -9,493.42 | 5,834.608 | 5,496.703 | 3,171.169 | 5,846.77 | 8,616.627 |
| Income Before Tax Ratio
| -0.028 | 0.017 | -0.048 | -0.213 | -0.128 | 0.013 | 0.072 | 0.058 | -0.084 | 0.007 | 0.011 | -0.094 | 0.046 | 0.052 | 0.033 | 0.076 | 0.141 |
| Income Tax Expense
| 92.609 | -5,323.849 | 206.138 | 458.503 | 1,648.851 | 1,564.767 | 1,975.239 | 1,713.385 | 7,411.37 | 729.354 | 895.709 | 3,252.935 | 1,767.52 | 3,165.529 | 370.317 | 983.441 | 2,033.432 |
| Net Income
| -4,524.837 | 7,867.987 | -6,804.257 | -27,753.014 | -20,832.842 | 988.269 | 7,807.498 | 6,745.899 | -16,135.461 | 761.49 | 1,025.971 | -12,273.359 | 4,554 | 3,067.853 | 2,940.981 | 4,863.329 | 6,583.195 |
| Net Income Ratio
| -0.027 | 0.052 | -0.049 | -0.217 | -0.139 | 0.007 | 0.056 | 0.047 | -0.129 | 0.007 | 0.01 | -0.122 | 0.036 | 0.029 | 0.03 | 0.063 | 0.108 |
| EPS
| -134.35 | 232.74 | -201.27 | -948.05 | -832.04 | 39.94 | 305.36 | 292.95 | -758.86 | 35.49 | 48.2 | -577.27 | 257.71 | 188.31 | 181.35 | 327 | 529.74 |
| EPS Diluted
| -134.35 | 232.74 | -201.27 | -948.05 | -832.04 | 39.94 | 305.36 | 292.95 | -758.86 | 35.49 | 48.2 | -577.27 | 257.71 | 188.31 | 181.35 | 327 | 529.74 |
| EBITDA
| 4,526.452 | 10,753.651 | -254.678 | -23,090.595 | -8,635.764 | 8,651.838 | 14,708.628 | 12,944.314 | -6,266.992 | 6,536.031 | 7,822.352 | -1,295.555 | 13,562.968 | 12,759.075 | 10,132.211 | 9,525.825 | 10,871.716 |
| EBITDA Ratio
| 0.027 | 0.071 | -0.002 | -0.181 | -0.058 | 0.059 | 0.105 | 0.091 | -0.05 | 0.062 | 0.075 | -0.013 | 0.108 | 0.121 | 0.104 | 0.123 | 0.178 |